ATE471945T1 - Als medikament geeignete lösliche varianten des gp130-moleküls - Google Patents

Als medikament geeignete lösliche varianten des gp130-moleküls

Info

Publication number
ATE471945T1
ATE471945T1 AT06841152T AT06841152T ATE471945T1 AT E471945 T1 ATE471945 T1 AT E471945T1 AT 06841152 T AT06841152 T AT 06841152T AT 06841152 T AT06841152 T AT 06841152T AT E471945 T1 ATE471945 T1 AT E471945T1
Authority
AT
Austria
Prior art keywords
soluble
medication
molecule used
soluble variants
polypeptide
Prior art date
Application number
AT06841152T
Other languages
English (en)
Inventor
Dirk Seegert
Georg Waetzig
Original Assignee
Conaris Res Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Inst Ag filed Critical Conaris Res Inst Ag
Application granted granted Critical
Publication of ATE471945T1 publication Critical patent/ATE471945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
AT06841152T 2005-12-23 2006-12-22 Als medikament geeignete lösliche varianten des gp130-moleküls ATE471945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05028420A EP1801121A1 (de) 2005-12-23 2005-12-23 Lösliche Varianten des Moleküls gp130 nützlich als Arzneimittel
PCT/EP2006/012515 WO2007071449A1 (en) 2005-12-23 2006-12-22 Soluble gp130 molecule variants useful as a medicament

Publications (1)

Publication Number Publication Date
ATE471945T1 true ATE471945T1 (de) 2010-07-15

Family

ID=36233865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06841152T ATE471945T1 (de) 2005-12-23 2006-12-22 Als medikament geeignete lösliche varianten des gp130-moleküls

Country Status (9)

Country Link
US (1) US7851182B2 (de)
EP (2) EP1801121A1 (de)
JP (1) JP5390191B2 (de)
AT (1) ATE471945T1 (de)
AU (1) AU2006328909A1 (de)
CA (1) CA2633213A1 (de)
DE (1) DE602006015103D1 (de)
ES (1) ES2347694T3 (de)
WO (1) WO2007071449A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006016765D1 (de) 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
JP5424330B2 (ja) * 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
EP2050759A1 (de) * 2007-10-19 2009-04-22 CONARIS research institute AG Lösliche gp-130-Muteine mit verbesserter Bindungsaktivität
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
MA41114B1 (fr) 2014-12-01 2021-06-30 Ferring Bv Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif
WO2017106244A1 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Compositions and methods for regulatable antibody expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
AU778998B2 (en) * 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
CN1341121A (zh) * 1999-01-07 2002-03-20 利思进药品公司 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运
EP1148065B1 (de) * 2000-04-21 2008-01-02 CONARIS research institute AG Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
ATE384783T1 (de) * 2001-10-19 2008-02-15 Zymogenetics Inc Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
EP1491554A1 (de) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament
JP2008504012A (ja) * 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質

Also Published As

Publication number Publication date
DE602006015103D1 (de) 2010-08-05
EP1994053B1 (de) 2010-06-23
EP1994053A1 (de) 2008-11-26
WO2007071449A1 (en) 2007-06-28
EP1801121A1 (de) 2007-06-27
CA2633213A1 (en) 2007-06-28
JP2009520480A (ja) 2009-05-28
JP5390191B2 (ja) 2014-01-15
AU2006328909A1 (en) 2007-06-28
US20090227499A1 (en) 2009-09-10
US7851182B2 (en) 2010-12-14
ES2347694T3 (es) 2010-11-03

Similar Documents

Publication Publication Date Title
ATE471945T1 (de) Als medikament geeignete lösliche varianten des gp130-moleküls
Bai et al. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization
Andreotti Native state proline isomerization: an intrinsic molecular switch
Van Goethem et al. Structure–activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?
EA200801166A1 (ru) Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
TW200730539A (en) Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
Hovanessian Midkine, a cytokine that inhibits HIV infection by binding to the cell surface expressed nucleolin
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
JP2008500025A5 (de)
ATE473759T1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
Cohen et al. Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold
ATE457728T1 (de) Kristallstruktur des aurora-2 proteins und dessen bindungstaschen
UA98295C2 (ru) Опухолево-ассоциированный пептид, который неспецифически связывается с молекулами ii класса лейкоцитарного антигена человека (hla)
JP2012522529A5 (de)
Peng et al. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at μ, δ, and κ opioid receptors
Suzuki et al. Syndecan binding sites in the laminin α1 chain G domain
RU2014143639A (ru) Регулируемые протеазой антитела
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
Inokuchi et al. Potent CXCR4 antagonists containing amidine type peptide bond isosteres
Cai et al. Metal-assisted assembly and stabilization of collagen-like triple helices
Voltà-Durán et al. Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering
ATE491044T1 (de) Gene und polypeptide in verbindung mit brustkrebserkrankungen
Fox et al. Examination of glycosaminoglycan binding sites on the XCL1 dimer
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties